-+ 0.00%
-+ 0.00%
-+ 0.00%

Evolus publishes investor presentation outlining aesthetics growth strategy and Evolysse rollout

PUBT·05/04/2026 20:44:25
Listen to the news
Evolus publishes investor presentation outlining aesthetics growth strategy and Evolysse rollout
  • Evolus outlined strategy to expand from neurotoxins into hyaluronic acid dermal fillers, positioning Evolysse as multi-year growth driver alongside flagship Jeuveau.
  • Evolysse launched in US in Q2 2025, with Europe launch planned for Q2 2026 under Estyme brand.
  • Jeuveau US neurotoxin market share estimated at 14% in 2025, up from 4% in 2019, with international expansion highlighted as next leg of growth.
  • Adjusted EBITDA profitability targeted to begin in 2026, supported by cash-pay model and digital-first platform.
  • Revenue shown rising to USD 297.2 million in 2025 from USD 56.5 million in 2020, with loyalty enrollments surpassing 1.4 million in Q1 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.